MedTrace Logo

Whether Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients With Lung Cancer

NCT05034445 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2021-09-05

No results posted yet for this study

Summary

This study intends to use Onconscreen plus 520 Panel (Burning Rock, China) to conduct NGS testing in sputum, tissues and blood samples of patients with advanced NSCLC. In order to explore the use of sputum as a diagnosis method for NSCLC patients, we will collect relevant clinical information and follow-up treatment information. The primary endpoint will reveal the effectiveness, accuracy, and feasibility in sputum, as compared to tissues and blood samples. This study aims to study the feasibility and advantages/disadvantages of using sputum as an noval body fluid biopsy option.

Conditions

Interventions

DIAGNOSTIC_TEST

Next generation sequencing

Extract DNA from sputum sample, minimum DNA amount should be over 50ng.

Sponsors & Collaborators

  • Guangzhou Institute of Respiratory Disease

    lead OTHER

Principal Investigators

  • Chengzhi Zhou, Dr. PhD. · The First Affiliated Hospital of Guangzhou Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-30
Primary Completion
2021-04-20
Completion
2021-04-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05034445 on ClinicalTrials.gov